Baxter/BMS/3M breast implant settlement needs board approval by Nov. 13.
This article was originally published in The Gray Sheet
BAXTER/BRISTOL-MEYERS SQUIBB/3M BREAST IMPLANT SETTLEMENT would provide $10,000-600,000 in compensation on a per-patient basis, substantially less than the amount promised under the original "global" class action settlement. Judge Samuel Pointer of the U.S. District Court of Alabama approved the agreement on Oct. 7, signing off on a deal that would cover only recipients of Baxter, Bristol-Myers Squibb and 3M implants.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.